|
Characterization of the deterioration of diabetes control in patients with a subsequent diagnosis of pancreatic cancer: A descriptive study.
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift) |
|
ID |
4658330 |
Author(s) |
Mueller, Alexandra M; Meier, Christoph R; Jick, Susan S; Schneider, Cornelia |
Author(s) at UniBasel |
Meier, Christoph R.
|
Year |
2022 |
Title |
Characterization of the deterioration of diabetes control in patients with a subsequent diagnosis of pancreatic cancer: A descriptive study. |
Journal |
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] |
Volume |
22 |
Number |
3 |
Pages / Article-Number |
387-395 |
Keywords |
CPRD; HbA(1c); Pancreatic cancer; Type 2 diabetes; Weight |
Mesh terms |
Blood Glucose; Body Weight; Diabetes Mellitus, Type 2, complications, diagnosis, drug therapy; Glycated Hemoglobin, analysis; Humans; Hypoglycemic Agents, therapeutic use; Pancreatic Neoplasms, complications, diagnosis, drug therapy |
Abstract |
Deterioration of diabetes control can be the first harbinger of pancreatic cancer. However, little is known about how to distinguish patients with pancreatic cancer-related diabetes deterioration from those with type 2 diabetes progression. We aimed to characterize the glycated hemoglobin (HbA; 1c; ) and body weight profile of pancreatic cancer patients with deteriorating diabetes before the cancer diagnosis.; Using data from the UK-based Clinical Practice Research Datalink (CPRD) GOLD, we established a study population including pancreatic cancer patients with diabetes deterioration in the >0.5-3 years before the cancer diagnosis and non-cancer patients with deterioration of type 2 diabetes (comparison group). Patients were considered to have diabetes deterioration if their glucose-lowering treatment was intensified. We characterized the longitudinal trajectories of HbA; 1c; and body weight in pancreatic cancer patients compared with non-cancer patients before and after treatment intensification.; The mean absolute increase in HbA; 1c; from the pre-deterioration period, i.e. the time >1-2 years before treatment intensification, to the time of treatment intensification, was 1.5% ± 1.6% in pancreatic cancer patients vs. 0.9% ± 1.4% in non-cancer patients. After treatment intensification, mean HbA; 1c; remained elevated in pancreatic cancer patients, while it returned to the pre-deterioration level in non-cancer patients. Body weight decreased by 1.9% ± 6.4% in cancer patients and increased by 0.3% ± 5.2% in non-cancer patients between the pre-deterioration period and treatment intensification, on average.; Pancreatic cancer-related diabetes deterioration may frequently be characterized by pronounced increases in HbA; 1c; , persistent elevation of HbA; 1c; after treatment intensification, and concomitant weight loss. |
ISSN/ISBN |
1424-3911 |
Full Text on edoc |
|
Digital Object Identifier DOI |
10.1016/j.pan.2022.03.012 |
PubMed ID |
http://www.ncbi.nlm.nih.gov/pubmed/35314354 |
|
|
|
MCSS v5.8 PRO. 0.361 sec, queries - 0.000 sec
©Universität Basel | Impressum
| |
01/05/2024
Research Database / FORSCHUNGSDATENBANK
|